Study to Evaluate Neuromodulation Subject Experience With Contemporary Spinal Cord Stimulation (SCS) Modalities for Chronic Pain (SENSE SCS)
Study to Evaluate Neuromodulation Subject Experience With Contemporary Spinal Cord Stimulation (SCS) Modalities for Chronic Pain (SENSE SCS Clinical Study)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Study Inbox
- Phone Number: 763-514-4000
- Email: rs.sensescsstudy@medtronic.com
Study Locations
-
-
California
-
Carlsbad, California, United States, 92009
- Coastal Research Institute
-
-
Florida
-
Fort Myers, Florida, United States, 33907
- Pain Management Consultants of Southwest Florida
-
-
Minnesota
-
Edina, Minnesota, United States, 55439
- Twin Cities Pain Clinic
-
-
New Jersey
-
Clifton, New Jersey, United States, 07013
- Garden State Pain and Orthopedics
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
- Novant Health Spine Specialists
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73134
- Oklahoma Pain Management
-
-
Pennsylvania
-
Sewickley, Pennsylvania, United States, 15143
- Pain Diagnostics and Interventional Care
-
-
Texas
-
Grapevine, Texas, United States, 76051
- North Texas Orthopedics and Spine Center
-
San Antonio, Texas, United States, 78235
- The San Antonio Orthopaedic Group
-
Shenandoah, Texas, United States, 77384
- Procura Pain and Spine PLLC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Pilot Phase Inclusion Criteria:
- 18 years of age or older
- A clinical decision was made for the patient to receive a commercial Medtronic SCS system (trial and implant) limited to the components for an on-label indication prior to enrollment in the study. NOTE: Vectris™ SureScan™ MRI 1x8 subcompact and Specify™SureScan™ MRI 2x8 leads are not eligible system components
- Able to differentiate between pain associated with the indication for SCS implant and other types of pain, as determined by the Investigator or designee
- Willing and able to use a personal smart phone for study surveys. NOTE: All subjects participating in the study must be willing to download the InsightPro™ clinical trial app and maintain current software updates on their own smart phone.
- Willing and able to provide signed and dated informed consent in English
- Willing and able to comply with all study procedures and visits
Pilot Phase Exclusion Criteria:
- Any active implantable neuromodulation device or system (e.g., Peripheral Nerve Stimulation, Sacral Neuromodulation)
- Currently participating, or plans to participate, in another investigational study or has a planned major medical procedure that may interfere with study procedures or confound study results, as determined by the Investigator or designee, unless documented pre-approval is provided by the sponsor
- Major untreated or refractory psychiatric comorbidity or other progressive disease (e.g., neurodegenerative disease, heart failure, cancer) that may confound study results, as determined by the Investigator or designee
- Serious drug-related behavioral issues (e.g., alcohol dependency, illegal substance abuse), as determined by the Investigator or designee
- Pregnant or planning on becoming pregnant
- Involved in an injury claim under current litigation, beneficiary of an injury claim, or receiving worker's compensation
- Patients with buried lead trials/implants will be excluded from this study
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Pilot Phase Cohort
|
Spinal cord stimulation therapy delivered during trialing and following implant of commercially available neurostimulation systems
|
|
Data at Scale Phase Cohort
|
Spinal cord stimulation therapy delivered during trialing and following implant of commercially available neurostimulation systems
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of surveys completed from Baseline through the SCS Trial Period in the Pilot Phase Cohort.
Time Frame: Up to 28 days
|
The percentage of surveys with complete data collected via the InsightPro™ clinical trial app from Baseline through the SCS Trial Period, calculated as the number of surveys with complete data divided by the total number of expected surveys within the Pilot Phase Cohort, expressed as a percentage.
|
Up to 28 days
|
|
Rating on the 7-point scale of Patient Global Impression of Change (PGIC) at Month 3 in the Data at Scale Phase Cohort
Time Frame: Month 3
|
PGIC is a single question asking the subject to rate their improvement in pain condition on a 7-point scale from 1 (Very Much Improved) to 7 (Very Much Worse)
|
Month 3
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Mirit Argov, Medtronic
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MDT22020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.